IMV Inc. (IMV) Reports Q3 Loss of $0.16
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
IMV Inc. Announces Third Quarter 2019 Financial Results and Provides Corporate Update
November 8, 2019 7:05 AM ESTReported preliminary data from Phase 2 basket study of DPX-Survivac in multiple solid tumors at the ESMO annual meeting, showing treatment was well-tolerated and showed signs of clinical activity Entered into research collaboration with The Wistar Institute, leveraging DPX technology to develop targeted T cell therapy against BRAF mutation Multiple near-term readouts from Phase 2 studies of DPX-Survivac, including updated data from SPiReL in recurrent/refractory  DLBCL to be presented at ASH 2019 on December 8, 2019 and topline interim results from DeCidE1... More
